Our Managing Director and CEO, Mr. Hari Kiran Chereddi, was recently featured in Citeline Medtech Insight in an article titled: "Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access"
The article highlights India's strategic position amidst global medtech supply chain shifts, especially in response to newly imposed US tariffs on Indian medical devices.
Current Landscape: Tariffs and Opportunity
The US has introduced a 27% reciprocal tariff on medical device imports from India, temporarily reduced to 10% for a 90-day period starting April 9th, 2025. This policy shift comes at a time when global supply chains are undergoing significant restructuring.
A Call for Structural Change
In the article, Mr. Chereddi emphasized that these tariffs are more than a short-term trade issue—they represent a deeper shift in global sourcing models:
"The world relied too long on a cost-first model. With rising geopolitical tensions, companies are rethinking sourcing strategies. India is emerging as a trusted, neutral hub in this global reset."
India Beyond Cost: The New Value Proposition
Historically viewed as a low-cost destination, India is now being recognized for its potential in quality manufacturing, regulatory agility, and supply chain reliability—key attributes in a post-COVID, geopolitically sensitive world.
Key Challenges: Regulatory Imbalances
Despite growing capabilities, Indian manufacturers still face steep entry barriers in the US, particularly in regulatory approval. The article notes that FDA approval costs—ranging from $9,280 to over $540,000—remain a significant hurdle, while US firms enjoy relatively easy access to the Indian market.
Our Strategic Response
As leaders of HRV Pharma and New Horizon Global Pharma (NHG Pharma), we are committed to navigating these challenges by focusing on:
- Strengthening regulatory frameworks
- Investing in precision manufacturing
- Upgrading logistics and supply chain infrastructure
India's Role in the Global Medtech Reset
Rather than viewing these developments as setbacks, we see them as a strategic validation of India's role in the future of global medtech. The shift signals a need for collaboration over confrontation, and a more balanced, reciprocal regulatory ecosystem.
Looking Ahead
At HRV Pharma and NHG Pharma, we are committed to Mr. Chereddi's vision: to help India become a self-reliant yet globally integrated medtech hub. By championing quality, compliance, and innovation, we aim to convert today's challenges into tomorrow's competitive strengths.
Read the full article here:
Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access
